Home›Search›Journal for ImmunoTherapy of Cancer

Journal for ImmunoTherapy of Cancer

BMJ Publishing Group · United Kingdom · Est. 1973

ISSN2051-1426eISSN2051-1426

SJR Q1✓ WOS SCIE✓ Scopus / SJR✓ DOAJ✓ Open Access

Impact Factor & Quartile · Web of Science (JCR)

✓ Indexed in the Web of Science Core Collection (SCIE) — Clarivate publishes an official Journal Impact Factor and JCR quartile for this journal.

See the official Impact Factor & quartile on the journal’s page ↗

The Impact Factor & JCR quartile are licensed by Clarivate — we link you to the official source instead of reprinting a number that can go out of date. Open metrics below: SCImago Q1 · Scopus CiteScore 17.8. Source: Clarivate Journal Citation Reports.

📊 Standing in its field

Where this journal ranks among others in the same subject area.

SJR · Scopus

Top 25% in field

Clarivate’s JCR quartile is a separate ranking and may differ

SJR Scorei

4.114

H-Indexi

179

CiteScorei

17.8

SNIPi

1.745

Total Worksi

5,645

Total Citationsi

198,805

2yr Mean Citednessi

7.34

Open Impact Factor alternative

Retractions

Source: Retraction Watch

Aims & Scope

The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer-reviewed journal that aims to enrich communication and advance scientific understanding in the rapidly evolving fields of tumor immunology and cancer immunotherapy. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

General Information

Country / RegionUnited Kingdom

Primary LanguageEnglish

1st Year Published1973

Annual Volume~ 553 articles / year

StatusActive (last: 2026)

Total Publications5,645

Publisher OrgBMJ

OA Since2012

Visit Journal Website

Submission Info

Peer ReviewSingle-blind

OA LicenseCC BY, CC BY-NC, CC BY-NC-ND

OA Rate—

Ethics & Quality

COPE Member✗ No

OASPA Member✗ No

Not on Predatory Lists✓ Yes

Plagiarism Detection✓ Yes

📦 Long-term Preservation

LOCKSSPMC

Think.Check.Submit Compliance

thinkchecksubmit.org

10/11 · 91%

✅

Do you know the journal / publisher?

BMJ Publishing Group

✅

Does the journal have a website?

✓ Linked

✅

Is the ISSN verified?

2051-1426 / 2051-1426

✅

Indexed in a trusted database?

WoS, Scopus, DOAJ, PubMed

✅

Peer review process documented?

Single-blind

❌

Follows ethical publishing standards (COPE)?

N/A

✅

Not on predatory/blacklists?

✓ Clean

✅

Long-term digital preservation?

LOCKSS, PMC

✅

Plagiarism detection in place?

Yes

✅

Listed in DOAJ (verified OA)?

DOAJ verified

✅

Primary language documented?

English

A twelfth criterion — whether APC fees are clearly disclosed — is not scored here; it is left out of the total rather than counted as a failure. Publication charges appear in the metrics card above.

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Publication & Citation Trend

Articles published

Citations received

365

36k

2019

563

38k

2020

645

34k

2021

566

26k

2022

476

14k

2023

479

2024

704

5.4k

2025

388

306

2026

Source: OpenAlex · Each year’s green bar = citations earned by that year’s papers, counted to date — so recent years look lower simply because their papers haven’t had time to be cited yet.

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.

Cancer ResearchQ1

ImmunologyQ1

Immunology and AllergyQ1

Molecular MedicineQ1

OncologyQ1

PharmacologyQ1

Subject Classification

Web of Science Categories

ImmunologyOncology

Scopus Categories

Molecular MedicinePharmacologyImmunologyCancer ResearchImmunology and AllergyOncology

Research Topics (OpenAlex)

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy researchImmune Cell Function and InteractionImmune cells in cancerMonoclonal and Polyclonal Antibodies ResearchVirus-based gene therapy researchFerroptosis and cancer prognosisCancer Research and TreatmentsT-cell and B-cell Immunology

Frequently asked questions about Journal for ImmunoTherapy of Cancer

Is Journal for ImmunoTherapy of Cancer a predatory journal?

PubScope has no integrity flags on record for Journal for ImmunoTherapy of Cancer: it is indexed in Web of Science, Scopus, DOAJ, and is not on DOAJ's withdrawn list. Indexing is a transparency signal, not a guarantee — always confirm fit and policies before submitting.

What is the impact factor of Journal for ImmunoTherapy of Cancer?

Journal for ImmunoTherapy of Cancer is indexed in the Web of Science Core Collection, so Clarivate publishes an official Journal Impact Factor for it (since the 2023 Journal Citation Reports, every Core Collection journal — including Arts & Humanities and Emerging Sources titles — receives one). PubScope links to Clarivate's official source rather than reprinting the number, which can be out of date. As an open alternative, its Scopus CiteScore is 17.8.

Is Journal for ImmunoTherapy of Cancer indexed in Scopus and Web of Science?

Journal for ImmunoTherapy of Cancer is indexed in Web of Science, Scopus, DOAJ.